AstraZeneca EBITDA 2010-2024 | AZN

AstraZeneca annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • AstraZeneca EBITDA for the quarter ending March 31, 2024 was $4.370B, a 7.87% increase year-over-year.
  • AstraZeneca EBITDA for the twelve months ending March 31, 2024 was $13.899B, a 25.2% increase year-over-year.
  • AstraZeneca 2023 annual EBITDA was $13.58B, a 47.02% increase from 2022.
  • AstraZeneca 2022 annual EBITDA was $9.237B, a 21.76% increase from 2021.
  • AstraZeneca 2021 annual EBITDA was $7.586B, a 8.72% decline from 2020.
AstraZeneca Annual EBITDA
(Millions of US $)
2023 $13,580
2022 $9,237
2021 $7,586
2020 $8,311
2019 $6,686
2018 $7,140
2017 $6,713
2016 $7,259
2015 $6,966
2014 $5,419
2013 $8,295
2012 $10,666
2011 $15,345
2010 $14,235
2009 $13,630
AstraZeneca Quarterly EBITDA
(Millions of US $)
2024-03-31 $4,370
2023-12-31 $2,561
2023-09-30 $3,236
2023-06-30 $3,732
2023-03-31 $4,051
2022-12-31 $2,575
2022-09-30 $2,579
2022-06-30 $1,896
2022-03-31 $2,187
2021-12-31 $1,900
2021-09-30 $1,114
2021-06-30 $1,880
2021-03-31 $2,692
2020-12-31 $2,284
2020-09-30 $1,972
2020-06-30 $1,994
2020-03-31 $2,061
2019-12-31 $2,220
2019-09-30 $1,473
2019-06-30 $1,220
2019-03-31 $1,773
2018-12-31 $2,739
2018-09-30 $1,549
2018-06-30 $1,447
2018-03-31 $1,405
2017-12-31 $1,793
2017-09-30 $1,804
2017-06-30 $1,541
2017-03-31 $1,575
2016-12-31 $3,123
2016-09-30 $1,639
2016-06-30 $890
2016-03-31 $1,607
2015-12-31 $1,804
2015-09-30 $1,741
2015-06-30 $1,639
2015-03-31 $1,782
2014-12-31 $672
2014-09-30 $1,392
2014-06-30 $1,807
2014-03-31 $1,548
2013-12-31 $2,014
2013-09-30 $2,094
2013-06-30 $2,139
2013-03-31 $2,048
2012-12-31 $2,728
2012-09-30 $2,901
2012-06-30 $2,378
2012-03-31 $2,659
2011-12-31 $3,137
2011-09-30 $4,805
2011-06-30 $3,476
2011-03-31 $3,927
2010-12-31 $4,136
2010-09-30 $3,008
2010-06-30 $3,299
2010-03-31 $3,792
2009-12-31 $3,738
2009-09-30 $3,608
2009-06-30 $3,001
2009-03-31 $3,283
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.255B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97